4.7 Review

Cardiorenal Syndrome The Emerging Role of Protein-Bound Uremic Toxins

Journal

CIRCULATION RESEARCH
Volume 111, Issue 11, Pages 1470-1483

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCRESAHA.112.278457

Keywords

cardiorenal syndrome; heart failure; interstitial fibrosis; myocardial infarction; uremic cardiomyopathy

Funding

  1. National Health and Medical Research Council of Australia [334008, 546272]
  2. Prince Doctor Fund (under the Royal Patronage of Her Royal Highness Princess Galyanivadhana), Chiang Mai University, Thailand
  3. National Health and Medical Research Council of Australia Program Grants

Ask authors/readers for more resources

Cardiorenal syndrome is a condition in which a complex interrelationship between cardiac dysfunction and renal dysfunction exists. Despite advances in treatment of both cardiovascular and kidney disease, cardiorenal syndrome remains a major global health problem. Characteristic of the pathophysiology of cardiorenal syndrome is bidirectional cross-talk; mediators/substances activated by the disease state of 1 organ can play a role in worsening dysfunction of the other by exerting their biologically harmful effects, leading to the progression of the syndrome. Accumulation of uremic toxins is a hallmark of renal excretory dysfunction. Removal of some toxins by conventional dialysis is particularly problematic because of their high protein binding. In this review, we demonstrate that protein-bound uremic toxins may play an important role in progression of cardiovascular disease in the setting of chronic kidney disease. The highly protein-bound uremic toxin indoxyl sulfate has emerged as a potent toxin adversely affecting both the kidney and heart. Direct cardiac effects of this toxin have been recently demonstrated both in vitro and in vivo. Specifically, potent fibrogenic and prohypertrophic effects, as well as oxidative stress-inducing effects, appear to play a central role in both renal and cardiac pathology. Many of these adverse effects can be suppressed by use of a gut adsorbent, AST-120. Potential mechanisms underlying indoxyl sulfate-induced cardiorenal fibrosis are discussed. Future research and clinical implications conclude this review. (Circ Res. 2012;111:1470-1483.)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Cardiac & Cardiovascular Systems

Sustained subcutaneous delivery of secretome of human cardiac stem cells promotes cardiac repair following myocardial infarction

Andrew R. Kompa, David W. Greening, Anne M. Kong, Paul J. McMillan, Haoyun Fang, Ritika Saxena, Raymond C. B. Wong, Jarmon G. Lees, Priyadharshini Sivakumaran, Andrew E. Newcomb, Bakhos A. Tannous, Cameron Kos, Lina Mariana, Thomas Loudovaris, Derek J. Hausenloy, Shiang Y. Lim

Summary: Subcutaneous implantation of TheraCyte devices containing the secretome of human cardiac stem cells attenuated adverse cardiac remodelling and preserved cardiac function following myocardial infarction. The secretome-based therapy led to reduced fibrosis, increased myocardial vascular density, and improved cardiac function.

CARDIOVASCULAR RESEARCH (2021)

Article Cardiac & Cardiovascular Systems

Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective

Feby Savira, Bing H. Wang, Andrew R. Kompa, Zanfina Ademi, Alice J. Owen, Sophia Zoungas, Andrew Tonkin, Danny Liew, Ella Zomer

Summary: The study found that adding dapagliflozin as an adjunct therapy to standard care for patients with chronic heart failure and reduced ejection fraction can prevent acute heart failure hospitalizations, increase years of life and quality-adjusted life-years, at a cost-effective ratio well below the Australian willingness-to-pay threshold.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2021)

Letter Cardiac & Cardiovascular Systems

RE: Inhibition of apoptosis signal-regulating kinase 1 might be a novel therapeutic target in the treatment of cardiorenal syndrome

Feby Savira, Amanda J. Edgley, Beat M. Jucker, Robert N. Willette, Henry Krum, Darren J. Kelly, Andrew R. Kompa, Bing H. Wang

INTERNATIONAL JOURNAL OF CARDIOLOGY (2021)

Letter Cardiac & Cardiovascular Systems

RE: Blockade of apoptosis signal-regulating kinase 1 ameliorates cardiac dysfunction in cardiorenal syndrome via enhancing angiogenesis

Feby Savira, Andrew R. Kompa, Amanda J. Edgley, Beat M. Jucker, Robert N. Willette, Darren J. Kelly, Bing H. Wang

INTERNATIONAL JOURNAL OF CARDIOLOGY (2021)

Article Medicine, Research & Experimental

β-blockade prevents coronary macro- and microvascular dysfunction induced by a high salt diet and insulin resistance in the Goto-Kakizaki rat

James T. Pearson, Hamish P. Thambyah, Mark T. Waddingham, Tadakatsu Inagaki, Vijayakumar Sukumaran, Jennifer P. Ngo, Connie P. C. Ow, Takashi Sonobe, Yi Ching Chen, Amanda J. Edgley, Yutaka Fujii, Cheng-Kun Du, Dong-Yun Zhan, Keiji Umetani, Darren J. Kelly, Hirotsugu Tsuchimochi, Mikiyasu Shirai

Summary: A high salt intake exacerbates insulin resistance and induces hypertension due to systemic perivascular inflammation, oxidative-nitrosative stress, and endothelial dysfunction. Treatment with ACE inhibitors and ARBs can alleviate inflammation and redox stress, but only partially restore endothelial function in mesenteric vessels. In male Goto-Kakizaki (GK) and Wistar rats, combination of high salt intake and insulin resistance leads to coronary microvessel endothelial dysfunction, which was restored by CAR and MET treatment, despite ongoing inflammation and oxidative-nitrosative stress.

CLINICAL SCIENCE (2021)

Article Medicine, Research & Experimental

Apoptosis signal-regulating kinase 1 inhibition reverses deleterious indoxyl sulfate-mediated endothelial effects

Feby Savira, Andrew R. Kompa, Ruth Magaye, Xin Xiong, Li Huang, Beat M. Jucker, Robert N. Willette, Darren J. Kelly, Bing H. Wang

Summary: The study showed that Indoxyl sulfate (IS) impairs endothelium-dependent vasorelaxation and endothelial cell migration, while inhibition of apoptosis signal regulating kinase 1 (ASK1) can alleviate these effects and promote autocrine interleukin 8 (IL-8) pro-angiogenic signaling.

LIFE SCIENCES (2021)

Article Medicine, Research & Experimental

NP202 treatment improves left ventricular systolic function and attenuates pathological remodelling following chronic myocardial infarction

Andrew R. Kompa, Fay L. Khong, Yuan Zhang, Cindy Nguyen, Amanda J. Edgley, Owen L. Woodman, Grant McLachlan, Darren J. Kelly

Summary: This study evaluated the efficacy of NP202, a synthetic flavonol, on cardiac remodelling in a chronic model of myocardial infarction (MI). Results showed that NP202 improved left ventricular function and structure, especially at a higher dose. NP202 also reduced hypertrophy and interstitial fibrosis in the non-infarct region of the myocardium.

LIFE SCIENCES (2022)

Article Toxicology

Sphingolipid imbalance and inflammatory effects induced by uremic toxins in heart and kidney cells are reversed by dihydroceramide desaturase 1 inhibition

Feby Savira, Ruth Magaye, Carmen Scullino, Bernard L. Flynn, Stuart M. Pitson, Dovile Anderson, Darren J. Creek, Yue Hua, Xin Xiong, Li Huang, Danny Liew, Christopher Reid, David Kaye, Andrew R. Kompa, Bing Hui Wang

Summary: This study assessed the effects of Des1 inhibition on PBUT-induced cardiac and renal effects, showing that Des1 inhibition attenuated negative effects on heart and kidney cells induced by PBUTs, such as hypertrophy and collagen synthesis, by modulating NF-κB signaling and reducing gene expression levels.

TOXICOLOGY LETTERS (2021)

Article Pharmacology & Pharmacy

The effect of dihydroceramide desaturase 1 inhibition on endothelial impairment induced by indoxyl sulfate

Feby Savira, Andrew R. Kompa, Darren J. Kelly, Ruth Magaye, Xin Xiong, Li Huang, Danny Liew, Christopher Reid, David Kaye, Carmen V. Scullino, Stuart M. Pitson, Bernard L. Flynn, Bing H. Wang

Summary: The study evaluated the therapeutic potential of using a Des1 inhibitor to mitigate the vascular effects caused by PBUT indoxyl sulfate. Inhibition of Des1 improved vascular relaxation and endothelial cell migration impaired by IS overload, suggesting that Des1 may be a suitable intracellular target to counteract the adverse vascular effects induced by PBUTs.

VASCULAR PHARMACOLOGY (2021)

Article Food Science & Technology

Aryl Hydrocarbon Receptor Inhibition Restores Indoxyl Sulfate-Mediated Endothelial Dysfunction in Rat Aortic Rings

Cindy Nguyen, Amanda J. Edgley, Darren J. Kelly, Andrew R. Kompa

Summary: This study investigates the effects of the uremic toxin indoxyl sulfate (IS) on vascular endothelial function and redox balance. The results indicate that IS impairs endothelium-dependent relaxation and increases the expression of oxidative stress markers. Inhibition of the aryl hydrocarbon receptor (AhR) could be a potential therapy for cardiovascular disease in the context of chronic kidney disease (CKD).

TOXINS (2022)

Review Pharmacology & Pharmacy

Targeting G protein-coupled receptors for heart failure treatment

Bui San Thai, Ling Yeong Chia, Anh T. N. Nguyen, Chengxue Qin, Rebecca H. Ritchie, Dana S. Hutchinson, Andrew Kompa, Paul J. White, Lauren T. May

Summary: Heart failure remains a significant cause of morbidity and mortality worldwide. Current treatment options have limitations, leading to many patients progressing to advanced stages. Exploration of novel therapeutics targeting G protein-coupled receptors (GPCRs) has shown promise, but efficacy and unwanted effects remain as challenges.

BRITISH JOURNAL OF PHARMACOLOGY (2023)

Article Cardiac & Cardiovascular Systems

The impact of coronary heart disease prevention on work productivity: a 10-year analysis

Feby Savira, Bing H. Wang, Andrew R. Kompa, Zanfina Ademi, Alice J. Owen, Danny Liew, Ella Zomer

Summary: This study aimed to determine the impact of preventing new cases of coronary heart disease on years of life and productivity over the next 10 years, using the novel measure PALY. The model predicted total years lived, PALYs, GDP, and potential benefits of preventing CHD in the Australian working-age population.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2021)

No Data Available